Teva Pharmaceutical Industries Limited American Depositary Shares - TEVA STOCK NEWS

Teva Pharmaceuticals presented new data at the Psych Congress Elevate 2024 regarding UZEDY® (risperidone), an extended-release injectable suspension for treating schizophrenia. Key findings include that switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provides a comparable pharmacokinetic (PK) profile. Additional Phase 3 RISE and SHINE studies showed no new safety concerns in young adults. The Global ADVANCE survey revealed real-world insights from healthcare professionals, caregivers, and patients on long-acting injectable (LAI) treatments. UZEDY can be administered subcutaneously without a loading dose, offering convenience and relapse prevention.

Teva Pharmaceuticals presented interim results from the Phase 4 IMPACT-TD Registry study at Psych Congress Elevate 2024, revealing that tardive dyskinesia (TD) significantly impacts patients' quality of life. The study involves 286 patients and shows that 98% of them experience TD's effects in daily life, with 83% facing moderate to severe impacts. Key findings include that TD affects social, psychological, and physical aspects even in mild cases. The study also evaluated the effectiveness of AUSTEDO XR and AUSTEDO tablets in treating TD.

Teva Pharmaceuticals announced that the U.S. FDA has approved AUSTEDO XR, an extended-release, once-daily tablet for treating tardive dyskinesia (TD) and Huntington’s disease (HD) chorea, available in four dosages (30, 36, 42, 48 mg). This approval offers flexibility and convenience for patients, with symptom improvement expected as early as two weeks for TD and significant reduction in chorea symptoms for HD. AUSTEDO XR is the only VMAT2 inhibitor without restrictions for use with CYP3A4/5 inducers or inhibitors. Over 90% of patients with insurance coverage will pay $10 or less for their prescription with financial assistance.

Teva Pharmaceutical Industries announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations, effective June 3, 2024. Shields succeeds Eric Drapé and will be based in Parsippany, NJ. Shields brings over 25 years of experience in biopharmaceutical and animal health industries, having held significant roles at Merck, Sanofi, and Amgen. At Merck, he supported $5.6 billion in annual sales and drove operational improvements. Teva CEO Richard Francis highlighted Shields' expertise as vital for the company's growth strategy. Drapé, who significantly contributed to Teva's operational agility and margin improvements, will depart after 11 years.

Teva reported Q1 2024 revenues of $3.8 billion, a 5% increase from Q1 2023, with growth in generics business and AUSTEDO. AJOVY revenues were up 18%. Positive Phase 3 results for olanzapine LAI (TEV' 749). Financial outlook reaffirmed for 2024. Gross profit increased by 12%. Non-GAAP diluted EPS was $0.48. Cash flow used in operating activities was $124 million. Debt decreased to $19,643 million. US segment revenues increased by 3%, led by AUSTEDO and generic products. Europe segment revenues grew by 7%, driven by generic products and AJOVY.

Teva Pharmaceuticals and Medincell have announced positive Phase 3 efficacy results from the SOLARIS trial evaluating TEV-‘749 (olanzapine) as a once-monthly subcutaneous long-acting injectable in adults with schizophrenia. The study met its primary endpoint, showing significant reductions in the PANSS total score across all dose groups compared to placebo. TEV-‘749 was well tolerated with no PDSS observed. The drug utilizes SteadyTeq™ technology, a copolymer technology proprietary to Medincell. The results demonstrate the potential of TEV-‘749 as an effective long-acting treatment option for schizophrenia.

Teva Pharmaceutical Industries announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on May 14, 2024. The presentation will be available via live webcast on Teva’s Investor Relations website.

Teva Pharmaceutical Industries released its 2023 Healthy Future Report, outlining a renewed sustainability strategy focused on achieving net zero emissions, renewable electricity, and health system strengthening. The report highlights the issuance of $2.49 billion in sustainability-linked bonds, bringing the total to $7.5 billion, making Teva the largest issuer in pharmaceuticals globally. Teva's efforts in access to medicines, greenhouse gas emission reductions, supplier engagement, and community support are detailed. The report reflects Teva's commitment to sustainability, business integrity, and social responsibility.